Allyl ether of mansonone G as a potential anticancer agent for colorectal cancer. 2022

Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
Interdisciplinary Program in Pharmacology, Graduate School, Chulalongkorn University, Bangkok, 10330, Thailand.

Mansonone G (MG), a 1,2-naphthoquinone isolated from the heartwood of Mansonia gagei Drumm, exhibited several pharmacological activities such as anti-bacterial, anti-estrogenic and anti-adipogenic effect. This study evaluated the cytotoxicity of MG and its derivatives as well as determined the mechanism(s) underlying the cytotoxic activity of the most potent MG derivative on two CRC cell lines, HCT-116 cells carrying p53 wild-type and HT-29 cells carrying p53 mutant. We found that MG and its derivatives could inhibit viability of HCT-116 and HT-29 cells in a concentration-dependent manner. Of all semi-synthetic derivatives of MG, allyl ether mansonone G (MG7) was the most potent cytotoxic agent toward cancer cells and less toxic to normal cells. MG7 could induce ROS generation which was associated with cytotoxicity and apoptosis in both HCT-116 and HT-29 cells. Western blot analysis revealed that MG7 downregulated the expression of Bcl-2 and Bcl-xL proteins in both CRC cell lines and upregulated the expression of BAK protein in HT-29 cells. Moreover, MG7 inhibited AKT signaling pathway in both CRC cell lines and modulated ERK1/2 signaling pathway by inhibiting ERK1/2 phosphorylation in HCT-116 cells and activating ERK1/2 phosphorylation in HT-29 cells. Molecular docking revealed that MG7 could bind to the ATP-binding pocket of AKT and ERK1 via hydrophobic interactions.

UI MeSH Term Description Entries
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D004986 Ether A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes. Diethyl Ether,Ether, Ethyl,Ethyl Ether,Ether, Diethyl
D005019 Ethyl Ethers Organic compounds having ethyl groups bound to an oxygen atom. Ethoxy Compounds,Compounds, Ethoxy,Ethers, Ethyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D051057 Proto-Oncogene Proteins c-akt Protein-serine-threonine kinases that contain PLECKSTRIN HOMOLOGY DOMAINS and are activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. They play a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells. akt Proto-Oncogene Protein,c-akt Protein,AKT1 Protein Kinase,AKT2 Protein Kinase,AKT3 Protein Kinase,Akt-alpha Protein,Akt-beta Protein,Akt-gamma Protein,Protein Kinase B,Protein Kinase B alpha,Protein Kinase B beta,Protein Kinase B gamma,Protein-Serine-Threonine Kinase (Rac),Proto-Oncogene Protein Akt,Proto-Oncogene Protein RAC,Proto-Oncogene Proteins c-akt1,Proto-Oncogene Proteins c-akt2,Proto-Oncogene Proteins c-akt3,RAC-PK Protein,Rac Protein Kinase,Rac-PK alpha Protein,Rac-PK beta Protein,Related to A and C-Protein,c-akt Proto-Oncogene Protein,Akt alpha Protein,Akt beta Protein,Akt gamma Protein,Akt, Proto-Oncogene Protein,Protein, akt Proto-Oncogene,Protein, c-akt Proto-Oncogene,Proteins c-akt1, Proto-Oncogene,Proteins c-akt2, Proto-Oncogene,Proteins c-akt3, Proto-Oncogene,Proto Oncogene Protein Akt,Proto Oncogene Protein RAC,Proto Oncogene Proteins c akt,Proto Oncogene Proteins c akt1,Proto Oncogene Proteins c akt2,Proto Oncogene Proteins c akt3,Proto-Oncogene Protein, akt,Proto-Oncogene Protein, c-akt,RAC PK Protein,RAC, Proto-Oncogene Protein,Rac PK alpha Protein,Rac PK beta Protein,Related to A and C Protein,akt Proto Oncogene Protein,alpha Protein, Rac-PK,c akt Proto Oncogene Protein,c-akt, Proto-Oncogene Proteins,c-akt1, Proto-Oncogene Proteins,c-akt2, Proto-Oncogene Proteins,c-akt3, Proto-Oncogene Proteins
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
December 2019, The Journal of pharmacy and pharmacology,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
November 2016, Bioorganic & medicinal chemistry letters,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
April 2012, Journal of traditional and complementary medicine,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
April 2014, Biochemical and biophysical research communications,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
February 2012, Carcinogenesis,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
January 2022, Frontiers in medicine,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
March 2012, Journal of dietary supplements,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
January 2023, Frontiers in pharmacology,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
January 2023, Oncology letters,
Savinee Chanvijit, and Suttinee Phuagkhaopong, and Panupong Mahalapbutr, and Methus Klaewkla, and Warinthorn Chavasiri, and Piyanuch Wonganan
November 2009, Medical hypotheses,
Copied contents to your clipboard!